Stocks and Investing Stocks and Investing
Fri, May 28, 2021

David Lebowitz Maintained (ASND) at Buy with Increased Target to $201 on, May 28th, 2021


Published on 2024-10-27 16:50:23 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $199 to $201 on, May 28th, 2021.

David has made no other calls on ASND in the last 4 months.



There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Tuesday, March 30th, 2021


This is the rating of the analyst that currently disagrees with David


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $190 on, Friday, March 12th, 2021
Contributing Sources